Europe Prophylaxis Of Organ Rejection Market
Taille du marché en milliards USD
TCAC :
% 
USD
839.28 Million
USD
1,087.24 Million
2021
2029
 Période de prévision |
2022 –2029 |
 Taille du marché (année de référence) |
USD 839.28 Million |
 Taille du marché (année de prévision) |
USD 1,087.24 Million |
 TCAC |
% |
| Principaux acteurs du marché |
Marché européen de la prophylaxie du rejet d'organes, par cause (exposition épidémiologique, prophylaxie antibactérienne, prophylaxie contre d'autres agents pathogènes et autres), traitement (immunosuppresseur ambulatoire, immunosuppresseur hospitalier et autres), voie d'administration (orale, intraveineuse), organe (rein, foie, cœur, poumon, autres), type de patient (pédiatrique, adulte), utilisateur final (hôpitaux, cliniques de soins à domicile et autres), canal de distribution (appel d'offres direct, pharmacies et autres), pays (Royaume-Uni, Allemagne, France, Espagne, Italie, Pays-Bas, Suisse, Russie, Belgique, Turquie et reste de l'Europe), tendances de l'industrie et prévisions jusqu'en 2029.
Analyse et perspectives du marché : Marché européen de la prophylaxie du rejet d'organes
La prophylaxie européenne du rejet d'organes devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2029. Data Bridge Market Research analyse que le marché européen croît avec un TCAC de 3,4 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 1 087,24 millions USD d'ici 2029 contre 839,28 millions USD en 2021. La prévalence croissante de la transplantation d'organes et l'utilisation accrue d'immunosuppresseurs seront probablement les principaux moteurs de la demande du marché au cours de la période de prévision.
Le terme prophylaxie désigne un traitement administré ou une action entreprise pour prévenir une maladie. La prophylaxie du rejet d'organe fait référence à la prévention du rejet d'organe par l'utilisation de médicaments. Les patients qui subissent une transplantation doivent être maintenus sous un régime d'immunosuppression pour la prophylaxie du rejet afin de garantir la survie du greffon. Le rejet de greffe est un processus dans lequel l'immunité du receveur de greffe est affaiblie par l'utilisation d' inhibiteurs de la calcineurine , d'inhibiteurs de mTOR, d'agents antimétabolites et de corticostéroïdes. Les agents de traitement améliorent les conséquences à court terme de la transplantation d'organe, mais certaines améliorations sont possibles. Les patients receveurs, qui ont subi une transplantation d'organe solide, doivent prendre des médicaments anti-rejet. En effet, le système immunitaire détruirait l'organe transplanté.
Les facteurs responsables de la croissance du marché nord-américain de la prophylaxie du rejet d'organes sont la prévalence accrue de la transplantation d'organes , l'augmentation des interventions chirurgicales, l'augmentation de la population de receveurs et le lancement de nouveaux produits. Cependant, les facteurs susceptibles de freiner le marché sont l'augmentation du coût de la procédure de transplantation, le manque de sensibilisation à la transplantation d'organes et les risques encourus par le patient lors de la réception de l'organe transplanté.
- D'autre part, les initiatives stratégiques des acteurs du marché, l'augmentation de la recherche et du développement et l'utilisation d'immunosuppresseurs peuvent constituer une opportunité pour la croissance du marché nord-américain de la prophylaxie du rejet d'organes. Le besoin d'expertise qualifiée et l'approbation réglementaire peuvent créer des défis pour le marché nord-américain de la prophylaxie du rejet d'organes. Des développements récents liés au marché nord-américain de la prophylaxie du rejet d'organes ont été observés.
Le rapport sur le marché européen de la prophylaxie du rejet d'organes fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché de la prophylaxie du rejet d'organes en Europe
Le marché européen de la prophylaxie du rejet d'organes est analysé et des informations sur la taille du marché sont fournies par cause, traitement, voie d'administration, organe, type de patient, utilisateur final et canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base de la cause, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en exposition épidémiologique, prophylaxie antibactérienne, prophylaxie contre d'autres agents pathogènes et autres. En 2022, le segment de l'exposition épidémiologique devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes en raison de la disponibilité d'informations directes et de la présence d'agents pathogènes liés à la prophylaxie du rejet d'organes aux États-Unis
- En fonction du traitement, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en immunosuppresseurs ambulatoires, immunosuppresseurs hospitaliers et autres. En 2022, le segment des immunosuppresseurs ambulatoires devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes, car il permet d'obtenir une réponse immunitaire soutenue et spécifique contre les cellules endommagées et la disponibilité de la cyclosporine aux États-Unis et au Canada.
- En Amérique du Nord, le marché de la prophylaxie du rejet d'organes est divisé en deux catégories : orale et intraveineuse, en fonction de la voie d'administration. En 2022, le segment oral devrait dominer le marché de la prophylaxie du rejet d'organes en Amérique du Nord en raison de la disponibilité et de la consommation accrues de comprimés et de gélules oraux.
- Sur la base des organes, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en rein, foie, cœur, poumon et autres. En 2022, le segment rénal devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes en raison de l'incidence accrue de l'insuffisance rénale et de la présence de politiques de remboursement telles que Medicare, pour l'assurance du receveur.
- En fonction du type de patient, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en pédiatrie et en adultes. En 2022, le segment des adultes devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes, en raison de la prévalence accrue des maladies chroniques et des conditions génétiques des patients adultes, de la faiblesse du système immunitaire chez les adultes et de la liste d'attente des receveurs adultes supérieure à la liste d'attente des enfants et des femmes au Nouveau-Mexique et aux États-Unis
- En fonction de l'utilisateur final, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en hôpitaux, cliniques, soins à domicile et autres. En 2022, le segment des hôpitaux devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes en raison de l'augmentation des soins médicaux et de la collaboration avec d'autres hôpitaux en Amérique du Nord pour la livraison des organes des donneurs aux patients receveurs.
- En fonction du canal de distribution, le marché nord-américain de la prophylaxie du rejet d'organes est segmenté en appels d'offres directs, pharmacies et autres. En 2022, le segment des appels d'offres directs devrait dominer le marché nord-américain de la prophylaxie du rejet d'organes en raison de la forte demande d'immunosuppresseurs ambulatoires par les sociétés pharmaceutiques et du paiement garanti, qui devraient dominer le marché.
Analyse du marché de la prophylaxie du rejet d'organes en Europe
Le marché européen de la prophylaxie du rejet d’organes est analysé et des informations sur la taille du marché sont fournies par cause, traitement, voie d’administration, organe, type de patient, utilisateur final et canal de distribution.
Les pays couverts par le rapport sur le marché européen de la prophylaxie du rejet d’organes sont le Royaume-Uni, l’Allemagne, la France, l’Espagne, l’Italie, les Pays-Bas, la Suisse, la Russie, la Belgique, la Turquie et le reste de l’Europe.
L'Europe devrait croître avec le TCAC au cours des périodes prévues, comme dans le cas des activités croissantes de R&D dans le secteur de la pneumologie. L'Allemagne devrait dominer le marché européen. L'Allemagne est l'un des principaux pays en raison de la présence d'acteurs majeurs du marché et des avancées technologiques accrues de la prophylaxie européenne du rejet d'organes dans la région.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Les initiatives stratégiques des acteurs du marché pour la prophylaxie du rejet d’organes créent de nouvelles opportunités sur le marché européen de la prophylaxie du rejet d’organes.
Le marché européen de la prophylaxie du rejet d'organes vous fournit également une analyse de marché détaillée pour la croissance de chaque pays dans un secteur particulier avec les ventes de prophylaxie du rejet d'organes en Europe, l'impact des progrès dans la prophylaxie du rejet d'organes en Europe et les changements dans les scénarios réglementaires avec leur soutien au marché européen des particules de prophylaxie du rejet d'organes. Les données sont disponibles pour la période historique de 2020 à 2021.
Analyse du paysage concurrentiel et des parts de marché de la prophylaxie du rejet d'organes en Europe
Le paysage concurrentiel du marché européen de la prophylaxie du rejet d'organes fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise par rapport au marché européen de la prophylaxie du rejet d'organes.
Les principales sociétés fournissant la prophylaxie du rejet d'organe en Europe sont Hansa Biopharma, Concord Biotech, Panacea Biotec, WOCKHARDT, SEBELA PHARMACEUTICALS, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy's Laboratories, Ltd, Viatris Inc, Strides Pharma Science Limited, Glenmark, Biocon, Pfizer Inc, Hikma Pharmaceuticals PLC, AbbVie Inc, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., CSL Behring entre autres.
Les initiatives stratégiques des acteurs du marché ainsi que les nouvelles avancées technologiques pour le marché européen de la prophylaxie du rejet d’organes comblent le fossé des médicaments.
Par exemple,
- En novembre 2020, Concord Biotech et Lupin ont reçu l'approbation de la FDA américaine pour les capsules d'immunosuppresseurs génériques. L'approbation reçue augmenterait la vente des capsules d'immunosuppresseurs utilisées dans le rejet d'organes. L'approbation reçue a assuré l'approbation post-commercialisation des capsules d'immunosuppresseurs génériques et leur mise à disposition dans les pharmacies et les magasins de détail.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 BY CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 EUROPE PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS
5.1.2 RISE IN CHRONIC DISEASES
5.1.3 RISE IN CLINICAL TRIALS
5.1.4 RISE IN RECIPIENT PATIENTS
5.1.5 PRODUCT APPROVALS
5.2 RESTRAINTS
5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE
5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION
5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN
5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION
5.3 OPPORTUNITIES
5.3.1 RISE IN RESEARCH AND DEVELOPMENTS
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT
5.4 CHALLENGES
5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION
5.4.2 STRINGENT REGULATIONS
6 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE
6.1 OVERVIEW
6.2 EPIDEMIOLOGIC EXPOSURE
6.2.1 HOSPITAL EXPOSURE
6.2.2 COMMUNITY EXPOSURE
6.3 ANTIBACTERIAL PROPHYLAXIS
6.3.1 POST-TRANSPLANT PROPHYLAXIS
6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS
6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS
6.5 OTHERS
7 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 OUTPATIENT IMMUNOSUPPRESSANT
7.2.1 CALCINEURIN INHIBITORS
7.2.1.1 CYCLOSPORINE
7.2.1.2 TACROLIMUS
7.2.1.2.1 IMMEDIATE RELEASE
7.2.1.2.2 EXTENDED RELEASE
7.2.2 CORTICOSTEROIDS
7.2.2.1 METHYLPREDNISOLONE
7.2.2.2 PREDNISONE
7.2.2.3 OTHERS
7.2.3 MYCOPHENOLIC ACIDS
7.2.3.1 MYCOPHENOLATE MOFETIL
7.2.3.2 MYCOPHENOLATE SODIUM
7.2.4 MTOR INHIBITORS
7.2.4.1 SIROLIMUS
7.2.4.2 EVEROLIMUS
7.2.5 AZATHIOPRINE
7.2.6 OTHERS
7.3 INPATIENT IMMUNOSUPPRESSANT
7.3.1 BELATACEPT
7.3.2 BASILIXIMAB
7.3.3 OTHERS
7.4 OTHERS
7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS
7.4.1.1 ERYTHROPOIETIN
7.4.1.2 DARBEPOETIN
7.4.2 ANTI-VIRAL AGENTS
7.4.2.1 VALGANCICLOVIR
7.4.2.2 LAMIVUDINE
7.4.2.3 ADEFOVIR
7.4.2.4 OTHERS
7.4.3 OTHERS
8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLET
8.2.1.1 IMMEDIATE RELEASE
8.2.1.2 EXTENDED-RELEASE
8.2.2 ORAL SOLUTION
8.2.3 OTHERS
8.3 INTRAVENOUS
9 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN
9.1 OVERVIEW
9.2 KIDNEY
9.3 LIVER
9.4 HEART
9.5 LUNG
9.6 OTHERS
10 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 PEDIATRIC
11 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 HOME HEALTHCARE
11.5 OTHERS
12 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 PHARMACY STORES
12.3.1 HOSPITAL PHARMACY
12.3.2 RETAIL PHARMACY
12.3.3 ONLINE PHARMACY
12.4 OTHERS
13 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION
13.1 EUROPE
13.1.1 FRANCE
13.1.2 SPAIN
13.1.3 U.K.
13.1.4 ITALY
13.1.5 GERMANY
13.1.6 POLAND
13.1.7 NETHERLANDS
13.1.8 SWEDEN
13.1.9 AUSTRIA
13.1.10 SWITZERLAND
13.1.11 NORWAY
13.1.12 HUNGARY
13.1.13 DENMARK
13.1.14 IRELAND
13.1.15 GREECE
13.1.16 LITHUANIA
13.1.17 REST OF EUROPE
14 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 EUROPE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 EUROPE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 13 EUROPE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 14 EUROPE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 15 EUROPE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 16 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 EUROPE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 EUROPE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 28 EUROPE KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 EUROPE ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 EUROPE HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 EUROPE DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 47 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 EUROPE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 EUROPE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 EUROPE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 55 EUROPE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 56 EUROPE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 57 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 58 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 59 EUROPE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 60 EUROPE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 61 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 EUROPE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 64 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 65 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 FRANCE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 FRANCE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 FRANCE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 FRANCE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 FRANCE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 FRANCE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 FRANCE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 FRANCE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 FRANCE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 FRANCE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 FRANCE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 84 FRANCE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 85 FRANCE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 86 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 87 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 FRANCE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 SPAIN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 92 SPAIN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 93 SPAIN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 SPAIN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 SPAIN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 97 SPAIN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 98 SPAIN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 99 SPAIN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 100 SPAIN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 SPAIN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 SPAIN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 SPAIN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 SPAIN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 SPAIN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 SPAIN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 109 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 SPAIN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 U.K. PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 114 U.K. EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 115 U.K. ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 116 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 U.K. OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 U.K. CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 U.K. TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 U.K. MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 U.K. MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 U.K. CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 U.K. INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 U.K. OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 U.K. ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 126 U.K. ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 127 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 U.K. ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 129 U.K. TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 130 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 131 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 U.K. PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 ITALY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 136 ITALY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 137 ITALY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 138 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 139 ITALY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 140 ITALY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 141 ITALY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 142 ITALY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 143 ITALY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 144 ITALY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 145 ITALY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 146 ITALY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 147 ITALY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 148 ITALY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 ITALY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 ITALY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 152 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 153 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 154 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 ITALY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 GERMANY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 158 GERMANY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 159 GERMANY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 160 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 GERMANY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 162 GERMANY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 163 GERMANY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 GERMANY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 165 GERMANY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 166 GERMANY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 167 GERMANY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 168 GERMANY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 169 GERMANY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 170 GERMANY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 171 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 172 GERMANY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 GERMANY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 175 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 176 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 GERMANY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 POLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 180 POLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 181 POLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 182 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 183 POLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 184 POLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 185 POLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 186 POLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 187 POLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 188 POLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 189 POLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 190 POLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 191 POLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 192 POLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 193 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 194 POLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 195 POLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 196 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 197 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 198 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 199 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 200 POLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 201 NETHERLANDS PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 202 NETHERLANDS EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 203 NETHERLANDS ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 204 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 205 NETHERLANDS OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 206 NETHERLANDS CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 207 NETHERLANDS TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 208 NETHERLANDS MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 209 NETHERLANDS MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 210 NETHERLANDS CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 211 NETHERLANDS INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 212 NETHERLANDS OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 213 NETHERLANDS ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 214 NETHERLANDS ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 215 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 216 NETHERLANDS ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 217 NETHERLANDS TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 218 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 219 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 220 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 222 NETHERLANDS PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 SWEDEN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 224 SWEDEN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 225 SWEDEN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 226 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 227 SWEDEN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 228 SWEDEN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 229 SWEDEN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 230 SWEDEN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 231 SWEDEN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 232 SWEDEN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 233 SWEDEN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 234 SWEDEN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 235 SWEDEN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 236 SWEDEN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 237 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 238 SWEDEN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 239 SWEDEN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 240 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 241 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 242 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 243 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 244 SWEDEN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 245 AUSTRIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 246 AUSTRIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 247 AUSTRIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 248 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 249 AUSTRIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 250 AUSTRIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 251 AUSTRIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 252 AUSTRIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 253 AUSTRIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 254 AUSTRIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 255 AUSTRIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 256 AUSTRIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 257 AUSTRIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 258 AUSTRIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 259 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 260 AUSTRIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 261 AUSTRIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 262 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 263 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 264 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 265 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 266 AUSTRIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 267 SWITZERLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 268 SWITZERLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 269 SWITZERLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 270 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 271 SWITZERLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 272 SWITZERLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 273 SWITZERLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 274 SWITZERLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 275 SWITZERLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 276 SWITZERLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 277 SWITZERLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 278 SWITZERLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 279 SWITZERLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 280 SWITZERLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 281 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 282 SWITZERLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 283 SWITZERLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 284 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 285 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 286 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 287 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 288 SWITZERLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 289 NORWAY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 290 NORWAY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 291 NORWAY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 292 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 293 NORWAY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 294 NORWAY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 295 NORWAY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 296 NORWAY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 297 NORWAY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 298 NORWAY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 299 NORWAY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 300 NORWAY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 301 NORWAY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 302 NORWAY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 303 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 304 NORWAY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 305 NORWAY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 306 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 307 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 308 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 309 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 310 NORWAY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 311 HUNGARY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 312 HUNGARY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 313 HUNGARY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 314 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 315 HUNGARY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 316 HUNGARY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 317 HUNGARY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 318 HUNGARY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 319 HUNGARY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 320 HUNGARY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 321 HUNGARY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 322 HUNGARY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 323 HUNGARY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 324 HUNGARY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 325 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 326 HUNGARY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 327 HUNGARY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 328 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 329 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 330 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 331 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 332 HUNGARY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 333 DENMARK PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 334 DENMARK EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 335 DENMARK ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 336 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 337 DENMARK OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 338 DENMARK CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 339 DENMARK TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 340 DENMARK MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 341 DENMARK MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 342 DENMARK CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 343 DENMARK INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 344 DENMARK OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 345 DENMARK ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 346 DENMARK ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 347 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 348 DENMARK ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 349 DENMARK TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 350 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 351 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 352 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 353 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 354 DENMARK PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 355 IRELAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 356 IRELAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 357 IRELAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 358 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 359 IRELAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 360 IRELAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 361 IRELAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 362 IRELAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 363 IRELAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 364 IRELAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 365 IRELAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 366 IRELAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 367 IRELAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 368 IRELAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 369 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 370 IRELAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 371 IRELAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 372 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 373 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 374 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 375 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 376 IRELAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 377 GREECE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 378 GREECE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 379 GREECE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 380 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 381 GREECE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 382 GREECE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 383 GREECE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 384 GREECE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 385 GREECE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 386 GREECE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 387 GREECE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 388 GREECE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 389 GREECE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 390 GREECE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 391 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 392 GREECE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 393 GREECE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 394 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 395 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 396 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 397 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 398 GREECE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 399 LITHUANIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 400 LITHUANIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 401 LITHUANIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 402 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 403 LITHUANIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 404 LITHUANIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 405 LITHUANIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 406 LITHUANIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 407 LITHUANIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 408 LITHUANIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 409 LITHUANIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 410 LITHUANIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 411 LITHUANIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 412 LITHUANIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 413 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 414 LITHUANIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 415 LITHUANIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 416 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 417 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 418 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)
TABLE 419 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 420 LITHUANIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 421 REST OF EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 2 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029
FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 EUROPE PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021
FIGURE 16 EUROPE PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021
FIGURE 17 EUROPE PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT
FIGURE 18 EUROPE PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET
FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020
FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE EUROPE SCENARIO, 2020
FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020
FIGURE 23 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021
FIGURE 24 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021
FIGURE 28 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 29 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 30 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 31 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021
FIGURE 36 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)
FIGURE 37 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)
FIGURE 38 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE
FIGURE 39 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021
FIGURE 40 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)
FIGURE 41 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 42 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 43 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021
FIGURE 44 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 45 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 46 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 48 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 49 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 50 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: SNAPSHOT (2021)
FIGURE 52 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2021)
FIGURE 53 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY CAUSE (2022-2029)
FIGURE 56 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
